Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
bioAffinity Technologies, Inc. ( (BIAF) ) has provided an update.
On February 25, 2026, bioAffinity Technologies announced a new validation study with Brooke Army Medical Center to test the clinical utility of its CyPath® Lung diagnostic on sputum samples obtained via tracheal and bronchial suctioning. The study, enrolling about 30–50 patients undergoing routine suctioning, is expected to report results by mid-2026.
By expanding CyPath® Lung sample collection beyond at-home sputum to deep suction samples gathered during procedures such as bronchoscopy, the study could accelerate adoption of the noninvasive test and better support diagnosis of indeterminate lung nodules. Given that roughly 500,000 bronchoscopies are performed annually in the U.S. within a market valued up to $920 million, successful validation could strengthen bioAffinity’s position in early lung cancer detection and enhance the clinical value of bronchoscopy-collected specimens.
BAMC’s role as a major academic medical center with a broad pulmonary patient base provides a robust setting for evaluating CyPath® Lung’s performance in real-world procedural workflows. The collaboration underscores demand from clinicians for complementary diagnostic tools and could broaden access to earlier, more informed decision-making for high-risk lung cancer patients.
The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection, with a particular emphasis on lung disease. Its first product, CyPath® Lung, is a laboratory-developed test that uses flow cytometry and AI to analyze sputum for early-stage lung cancer, and is marketed through its subsidiary Precision Pathology Laboratory Services.
CyPath® Lung has demonstrated high sensitivity, specificity and accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules, positioning bioAffinity in the growing market for advanced diagnostic tools. The company aims to address unmet needs in early-stage cancer diagnosis and broader lung disease assessment through innovative, AI-driven testing technologies.
Average Trading Volume: 146,172
Technical Sentiment Signal: Sell
Current Market Cap: $4.99M
For an in-depth examination of BIAF stock, go to TipRanks’ Overview page.